Inactivation of the RB1 tumor suppressor gene is common in several types of therapy-
resistant cancers, including metastatic castration-resistant prostate cancer, and predicts poor …

The androgen receptor (AR) signaling pathway is critical for growth and differentiation of
prostate cancer cells. For that reason, androgen deprivation therapy with medical or surgical …

Prostate cancer (PCa) is a non-cutaneous malignancy in males with wide variation in
incidence rates across the globe. It is the second most reported cause of cancer death. Its …

Abstract Lysine-specific demethylase 1 (LSD1) is a histone demethylase that promotes
stemness and cell survival in cancers such as prostate cancer. Most prostate malignancies …

The androgen receptor (AR) plays a pivotal role in driving prostate cancer (PCa)
development. However, when stimulated by high levels of androgens, AR can also function …

One critical mechanism through which prostate cancer (PCa) adapts to treatments targeting
androgen receptor (AR) signaling is the emergence of ligand-binding domain-truncated and …

Introduction The extensive heterogeneity of prostate cancer (PCa) and multilayered
complexity of progression to castration-resistant prostate cancer (CRPC) have contributed to …

Prostate cancer (PCa) is the second most frequent type of cancer in men and assessing
circulating tumor cells (CTCs) by liquid biopsy is a promising tool to help in cancer early …

Abstract Treatment-related neuroendocrine prostate cancer is a distinctive category of
prostate cancer that arises after intensive suppression of the androgen receptor by next …

The androgen receptor (AR) is the critical driver in prostate cancer and exerts its function
mainly through transcriptional control. Recent advances in clinical studies and cell line …